Bronstein, Gewirtz & Grossman LLC Urges Chemours Company Investors to Act: Class Action Filed Alleging Investor Harm

    129 Aufrufe 129 0 Kommentare 0 Kommentare
    Bronstein, Gewirtz & Grossman LLC Urges Chemours Company Investors to Act: Class Action Filed Alleging Investor Harm

    New York, New York--(Newsfile Corp. - October 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.

    This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit.

    Chemours Case Details

    The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:

    1. Defendants had materially overstated aftermarket demand for their Opteon products;
    2. demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year;
    3. as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and
    4. as a result, Defendants' public statements were materially false and misleading at all relevant times.

    What's Next for Chemours Investors?

    A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

    No Cost to Chemours Investors

    We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

    Why Bronstein, Gewirtz & Grossman, LLC for Chemours Securities Class Action?

    Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

    "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

    Follow us for updates on LinkedIn, X, Facebook, or Instagram.

    Contact Info

    Peretz Bronstein, Esq. or Nathan Miller
    Bronstein, Gewirtz & Grossman, LLC
    917-590-0911 | info@bgandg.com

    Attorney advertising.
    Prior results do not guarantee similar outcomes.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318449


    The The Chemours Stock at the time of publication of the news with a fall of -1,87 % to 11,79USD on Tradegate BSX stock exchange (13. Oktober 2026, 22:25 Uhr).





    Verfasst von newsfile
    Bronstein, Gewirtz & Grossman LLC Urges Chemours Company Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - October 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of …

    Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlagestrategien geeignet.
    Profitieren Sie von unserem Alleinstellungsmerkmal als den zentralen verlagsunabhängigen Wissens-Hub für einen aktuellen und fundierten Zugang in die Börsen- und Wirtschaftswelt, um strategische Entscheidungen zu treffen.
    • ✅ Größte Finanz-Community Deutschlands
    • ✅ über 550.000 registrierte Nutzer
    • ✅ rund 2.000 Beiträge pro Tag
    • ✅ verlagsunabhängige Partner ARIVA, FinanzNachrichten und BörsenNews
    • ✅ Jederzeit einfach handeln beim SMARTBROKER+
    • ✅ mehr als 25 Jahre Marktpräsenz
    Aktien von A - Z: # A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    wallstreetONLINE bei X wallstreetONLINE bei Instagram wallstreetONLINE bei Facebook wallstreetONLINE bei Youtube wallstreetONLINE bei LinkedIn
    Unsere Apps: Apple App Store Icon Google Play Store Icon
    Wenn Sie Kursdaten, Widgets oder andere Finanzinformationen benötigen, hilft Ihnen ARIVA gerne. 

    Unsere User schätzen wallstreet-online.de: 4.8 von 5 Sternen ermittelt aus 285 Bewertungen bei www.kagels-trading.de
    Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.
    Copyright © 1998-2026 Smartbroker Holding AG - Alle Rechte vorbehalten.
    Mit Unterstützung von: Ariva Smartbroker+
    Daten & Kurse von: TTMzero